{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 460033186
| IUPAC_name = 1,1',1<nowiki>''</nowiki>-(2-Chloroethene-1,1,2-triyl)tris(4-methoxybenzene); 11-chloro-4,13-dimethoxy-12-(''p''-methoxyphenyl)stilbene
| image = Chlorotrianisene.svg

<!--Clinical data-->
| tradename = Tace
| Drugs.com = {{drugs.com|MTM|chlorotrianisene}}
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = X
| pregnancy_category =  
| legal_AU = <!-- Unscheduled / S2 / S4 / S8 -->
| legal_UK = <!-- GSL / P / POM / CD -->
| legal_US = <!-- OTC / Rx-only -->
| legal_status = Discontinued
| routes_of_administration = [[Oral administration|Oral]]

<!--Pharmacokinetic data-->
| bioavailability =  
| protein_bound = 50 to 80%
| metabolism =  
| elimination_half-life =  
| excretion =  

<!--Identifiers-->
| IUPHAR_ligand = 7146
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 569-57-3
| ATC_prefix = G03
| ATC_suffix = CA06
| ATC_supplemental =  
| PubChem = 11289
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB00269
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 10815
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 6V5034L121
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D00269
| ChEBI_Ref = {{ebicite|correct|EBI}}
| ChEBI = 3641
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 1200761

<!--Chemical data-->
| C=23 | H=21 | Cl=1 | O=3
| molecular_weight = 380.864 g/mol
| smiles = Cl/C(c1ccc(OC)cc1)=C(/c2ccc(OC)cc2)c3ccc(OC)cc3
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C23H21ClO3/c1-25-19-10-4-16(5-11-19)22(17-6-12-20(26-2)13-7-17)23(24)18-8-14-21(27-3)15-9-18/h4-15H,1-3H3
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = BFPSDSIWYFKGBC-UHFFFAOYSA-N
| synonyms = NSC-10108
}}

'''Chlorotrianisene''' ([[International Nonproprietary Name|INN]], [[United States Adopted Name|USAN]], [[British Approved Name|BAN]]; brand names '''Tace''', '''Estregur''', '''Anisene''', '''Clorotrisin''', '''Merbentyl''', '''Triagen''', many others;  also known as '''CTA'''; '''tri-''p''-anisylchloroethylene''', '''TACE''', or '''tris(''p''-methoxyphenyl)chloroethylene''') is a [[Organic compound#Synthetic compounds|synthetic]], [[nonsteroidal]] [[estrogen]] of the [[triphenylethylene]] group that was formerly used for the treatment of [[menopause|menopausal]] symptoms, [[estrogen deficiency]], and [[prostate cancer]] before being discontinued.<ref name="Elks2014">{{cite book|author=J. Elks|title=The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies|url=https://books.google.com/books?id=0vXTBwAAQBAJ&pg=PA263|date=14 November 2014|publisher=Springer|isbn=978-1-4757-2085-3|pages=263–}}</ref><ref>{{cite book|title=Index Nominum 2000: International Drug Directory|url=https://books.google.com/books?id=5GpcTQD_L2oC&pg=PA219|date=January 2000|publisher=Taylor & Francis|isbn=978-3-88763-075-1|pages=219–}}</ref><ref name="MortonHall2012">{{cite book|author1=I.K. Morton|author2=Judith M. Hall|title=Concise Dictionary of Pharmacological Agents: Properties and Synonyms|url=https://books.google.com/books?id=tsjrCAAAQBAJ&pg=PA73|date=6 December 2012|publisher=Springer Science & Business Media|isbn=978-94-011-4439-1|pages=73–}}</ref> It was approved in the [[United States]] as '''TACE''' in 1952, and was introduced throughout [[Europe]] subsequently.<ref name="Publishing2013">{{cite book|author=William Andrew Publishing|title=Pharmaceutical Manufacturing Encyclopedia, 3rd Edition|url=https://books.google.com/books?id=_J2ti4EkYpkC&pg=PA980|date=22 October 2013|publisher=Elsevier|isbn=978-0-8155-1856-3|pages=980–}}</ref> CTA was the first estrogenic compound of the triphenylethylene series to be introduced.<ref name="FischerGanellin2012">{{cite book|author1=Janos Fischer|author2=C. Robin Ganellin|author3=David P. Rotella|title=Analogue-based Drug Discovery III|url=https://books.google.com/books?id=BP2Bo11gTOMC&pg=SA5-PA56|date=15 October 2012|publisher=John Wiley & Sons|isbn=978-3-527-65110-8|pages=5–}}</ref>

CTA was derived from [[estrobin]] (DBE), a [[chemical derivative|derivative]] of the very weakly estrogenic compound [[triphenylethylene]] (TPE), which in turn was derived from structural modification of [[diethylstilbestrol]] (DES).<ref name="Meikle2003">{{cite book|author=A. Wayne Meikle|title=Endocrine Replacement Therapy in Clinical Practice|url=https://books.google.com/books?id=CA0HCAAAQBAJ&pg=PA486|date=24 April 2003|publisher=Springer Science & Business Media|isbn=978-1-59259-375-0|pages=486–}}</ref><ref name="Sneader2005">{{cite book|author=Walter Sneader|title=Drug Discovery: A History|url=https://books.google.com/books?id=Cb6BOkj9fK4C&pg=PA198|date=23 June 2005|publisher=John Wiley & Sons|isbn=978-0-471-89979-2|pages=198–}}</ref><ref name="pmid3905383">{{cite journal | vauthors = Jordan VC, Mittal S, Gosden B, Koch R, Lieberman ME | title = Structure-activity relationships of estrogens | journal = Environ. Health Perspect. | volume = 61 | issue = | pages = 97–110 | year = 1985 | pmid = 3905383 | pmc = 1568776 | doi = 10.1289/ehp.856197| url = }}</ref><ref name="AvendanoMenendez2015">{{cite book|author1=Carmen Avendano|author2=J. Carlos Menendez|title=Medicinal Chemistry of Anticancer Drugs|url=https://books.google.com/books?id=VEibBwAAQBAJ&pg=PA87|date=11 June 2015|publisher=Elsevier Science|isbn=978-0-444-62667-7|pages=87–}}</ref> CTA is a relatively weak estrogen, with about one-eighth the potency of DES.<ref name="Meikle2003" /><ref name="Sneader2005" /> However, it is highly [[lipophilic]] and is stored in [[fat tissue]] for prolonged periods of time, with its slow release from fat resulting in a very long duration of action.<ref name="Meikle2003" /><ref name="Sneader2005" /><ref name="pmid3905383" /> CTA itself is inactive; it behaves as a [[prodrug]] to a weak estrogen that is formed as a [[metabolite]] via degradation of CTA in the [[liver]].<ref name="Meikle2003" /><ref name="Hadden2013">{{cite book|author=John Hadden|title=Pharmacology|url=https://books.google.com/books?id=fmfSBwAAQBAJ&pg=PA249|date=9 November 2013|publisher=Springer Science & Business Media|isbn=978-1-4615-9406-2|pages=249–}}</ref> As such, the potency of CTA is reduced if it is given [[parenteral]]ly instead of orally.<ref name="Meikle2003" />

Although it is referred to as a weak estrogen and was used solely as an estrogen in clinical practice, CTA is a [[partial agonist]] of the [[estrogen receptor]].<ref name="Sneader2005" /> As such, it is a [[selective estrogen receptor modulator]] (SERM), with predominantly estrogenic but also [[antiestrogen]]ic effects, and was arguably the first SERM to ever be introduced.<ref name="FischerGanellin2012">{{cite book|author1=Janos Fischer|author2=C. Robin Ganellin|author3=David P. Rotella|title=Analogue-based Drug Discovery III|url=https://books.google.com/books?id=BP2Bo11gTOMC&pg=SA5-PA56|date=15 October 2012|publisher=John Wiley & Sons|isbn=978-3-527-65110-8|pages=5–}}</ref> CTA can antagonize [[estradiol]] at the level of the [[hypothalamus]], resulting in disinhibition of the [[hypothalamic-pituitary-gonadal axis]] and an increase in estrogen levels.<ref name="Sneader2005" /> [[Clomifene]] and [[tamoxifen]] were both derived from CTA via structural modification, and are much weaker partial agonists than CTA and hence much more antiestrogenic in comparison.<ref name="Sneader2005" /> As an example, chlorotrianisene produces [[gynecomastia]] in men,<ref name="Li2009">{{cite book|author=Jie Jack Li|title=Triumph of the Heart: The Story of Statins|url=https://books.google.com/books?id=-GPl1PA5EgMC&pg=PA34|date=3 April 2009|publisher=Oxford University Press, USA|isbn=978-0-19-532357-3|pages=34–}}</ref> albeit reportedly to a lesser extent than other estrogens,<ref>{{cite book|title=VITAMINS AND HORMONES|url=https://books.google.com/books?id=5ZbLRONHoDoC&pg=PA387|date=18 May 1976|publisher=Academic Press|isbn=978-0-08-086630-7|pages=387–}}</ref> while clomifene and tamoxifen do not and can be used to treat gynecomastia.<ref name="Khan2003">{{cite journal|last1=Khan|first1=H. N|title=Endocrine treatment of physiological gynaecomastia|journal=BMJ|volume=327|issue=7410|year=2003|pages=301–302|issn=0959-8138|doi=10.1136/bmj.327.7410.301}}</ref>

==See also==
* [[Ethamoxytriphetol]]
* [[Broparestrol]]
* [[Methallenestril]]
* [[Stilbestrol]]

==References==
{{Reflist|2}}


{{Estrogens and antiestrogens}}
{{Estrogen receptor modulators}}

[[Category:Organochlorides]]
[[Category:Phenol ethers]]
[[Category:Prodrugs]]
[[Category:Selective estrogen receptor modulators]]
[[Category:Synthetic estrogens]]
[[Category:Triphenylethylenes]]